Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 6/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 3/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23540926 | 0.93 | NAMPT (0.41) | PRMT5GPR119WDR77GRM5NAMPT | |
| SCHEMBL30273631 | 0.93 | TLR9 (0.36) | TLR9TLR7PRMT5GPR119GRM5 | |
| SCHEMBL23540770 | 0.87 | TLR9 (0.34) | TLR9TLR7PRMT5GPR119GRM5 | |
| SCHEMBL31323560 | 0.85 | PRMT5 (0.37) | TLR9TLR7PRMT5GPR119MEN1 | |
| SCHEMBL23540834 | 0.84 | NAMPT (0.40) | PRMT5GPR119WDR77GRM5NAMPT | |
| SCHEMBL30026606 | 0.84 | NAMPT (0.40) | PRMT5GPR119WDR77GRM5NAMPT | |
| SCHEMBL30273787 | 0.83 | NAMPT (0.38) | TLR9TLR7PRMT5GPR119WDR77 | |
| SCHEMBL24821127 | 0.83 | GRM5 (0.35) | PRMT5GRM5PKM | |
| SCHEMBL23541226 | 0.83 | GHSR (0.35) | TLR9TLR7PRMT5GPR119GRM5 | |
| SCHEMBL31397309 | 0.83 | GHSR (0.35) | TLR9TLR7PRMT5GPR119GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | CALICO LIFE SCIENCES LLC (US) | 2024-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | PTPN1, PTPN2, PTPN5 | TLR9 3300/4885TLR7 3400/4885PRMT5 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.